BioSpace News Archive

Sudo Biosciences announced the close of a $116 million Series B financing round co-led by Enavate Sciences and TPG, which is investing in the company through TPG Life Sciences Innovations and The Rise Fund, with participation from Sanofi Ventures, Surveyor Capital, Monograph Capital, and Eventide Asset Management as well as existing investors Frazier Life Sciences and Velosity Capital.

Coya Therapeutics, Inc. announced that it has appointed Secretary Wilbur Ross to its board of directors, effective immediately.

Ocelot Bio, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its lead candidate OCE-205 for the treatment of ascites due to all etiologies except cancer.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) is pleased to report unprecedented preliminary survival and clinical benefit data in a new subset of advanced breast cancer patients treated with BriaCell’s Bria-IMT™ regimen: patients that have developed resistance to (and failed to respond to) Antibody-Drug Conjugates (“ADC”, “ADCs”).

Adial Pharmaceuticals, Inc. announced that on December 16, 2023, it received the final development cost reimbursement payment of $350,000 from Adovate, LLC under the terms of the final asset purchase agreement executed with Adovate for purchase of the assets and business of the Company’s wholly owned subsidiary, Purnovate, Inc.

The FDA has officially approved Signati™ Medical’s Investigational Device Exemption (IDE) study! This comes on the company’s 5 year anniversary.

Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that according to prescription data from Symphony Health, ZTlido® is the most prescribed non-opioid, branded pain treatment prescribed by pain specialists.

Agilent Technologies Inc. announced it has moved the company’s Cell Analysis Division into its Diagnostics and Genomics Group as part of a strategy to further strengthen growth opportunities for both organizations.

insitro, a machine learning-powered drug discovery and development company, today announced that Daphne Koller, Ph.D., founder and CEO, will present a company overview, including recent business and research highlights, at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 3:30 p.m. PT.

Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce that the Food and Drug Administration has granted RadioGel Precision Radionuclide Therapy the designation as a Breakthrough Device pursuant to the FDA’s Breakthrough Devices Program.